The news: On Friday, two important developments related to AI-powered cancer diagnostics surfaced:
1. Memorial Sloan Kettering’s spinout, Paige, got FDA clearance for its AI-powered clinical decision support tool to detect prostate cancer.
2. NYU Langone Health released study results showing its AI tool for breast cancer imaging improved the accuracy of diagnoses:
Why it matters: Breast cancer and prostate cancer are among the most common cancers in the US—and cancer is the second leading cause of death in the US.
Trendspotting: Embedding AI into medical imaging systems is taking off as a promising approach to producing early cancer diagnoses (which can often be life-saving).
The bigger picture: AI investments in cancer care are only accelerating among hospitals and health systems, and positive traction like the FDA’s stamp of approval and rosy clinical trial results will only keep the needle moving faster.
Go deeper: To learn more about how digital health companies are disrupting the healthcare AI space, check out our AI in Healthcare Administration report here. (edited)
11 Times SquareNew York, NY 100361-800-405-0844